Neopharma Technologies Partners with Exchange Listing for U.S. IPO Management

On August 5, 2025, Neopharma Technologies Ltd (NTL), a prominent player in the MedTech industry, announced its strategic partnership with Exchange Listing, LLC. This collaboration aims to manage Neopharma’s forthcoming initial public offering (IPO) in the United States. The company plans to list on the NASDAQ Stock Exchange, a move signaling its robust growth and market ambitions.

Neopharma Technologies is lauded for its innovative contributions to digital drug and impairment testing solutions aimed at ensuring workplace and public safety. This unique focus positions the company at the vanguard of technological and regulatory shifts within the healthcare landscape.

One of the key products underpinning Neopharma’s reputation is its NEOVAULT® platform. This groundbreaking solution stands as the world’s first integrated chain-of-custody and data management system tailored specifically for point-of-care (POC) drug testing. By combining NEOVAULT® with its NEOTEST® range of regulatory-grade oral and urine screening devices, Neopharma provides a secure and mobile solution that enhances compliance and operational safety across various sectors including enterprises, governmental bodies, and healthcare organizations.

Neopharma's offerings align closely with the evolving global regulatory landscape. Notably, in April 2025, the White House Office of National Drug Control Policy endorsed the use of AI-powered digital drug testing technologies. NEOVAULT® has achieved notable certifications, being included among the few globally recognized platforms that meet this standard. It stands out as the exclusive solution certified under several crucial frameworks including HIPAA, SOC 2 Type 2, GDPR, and ISO 27001.

As the company gears up for its IPO, commercial interest in Neopharma’s products is rapidly increasing. It is currently in advanced discussions or negotiations with major manufacturers, including four of the world’s largest producers of Drugs of Abuse (DOA) test kits, to enhance over 150 million drug test kits with NEOVAULT® technology. Additionally, Neopharma is engaging with multiple international distributors and has established partnerships with 25 enterprise clients spanning Australia and New Zealand. This strategic foundation is designed to support a high-margin, recurring revenue model through SaaS and platform licensing, providing Neopharma with sustainable growth avenues.

Peter Goldstein, CEO of Exchange Listing, expressed confidence in Neopharma’s suitability for the U.S. capital markets. He noted, “Neopharma's platform, business model, and traction make it an ideal candidate for the U.S. capital markets. We’re confident in Shaun and Marcus's leadership and committed to guiding the company through a successful Nasdaq listing aligned with its long-term growth strategy.”

Shaun Melville, Executive Director at Neopharma Technologies, highlighted the importance of this partnership: “Exchange Listing brings the IPO expertise and strategic insight we need as we expand globally. NEOVAULT® is solving real compliance and public safety challenges. We're ready to scale this solution worldwide.”

In summary, Neopharma Technologies Ltd is carving a path in the digital health domain with its innovative drug testing solutions. The partnership with Exchange Listing, LLC represents a significant step forward as they prepare for their U.S. IPO, signaling a new chapter for the company and its commitment to enhancing public safety through technology.

About Neopharma Technologies Ltd

Neopharma Technologies is at the forefront of delivering advanced digital solutions for secure, real-time drug screening and compliance management. Its NEOVAULT® platform and NEOTEST® devices cater to enterprise, healthcare, and government clients worldwide.

About Exchange Listing, LLC

Exchange Listing specializes in providing capital markets advisory and IPO readiness services for growth-stage companies aiming for listings on both the Nasdaq and NYSE.